Lev Pharmaceuticals Inc

Lev Pharmaceuticals — Merger or Acquisition (July 2008)

29 slides from Lev Pharmaceuticals's merger presentation, Jul 16, 2008

  1. Slide 1: Acquisition of LEV Pharmaceuticals

    in ° VIROPHARMA , Qh nm OX Re ‘ViroPharma Incorporated Acquisition of LEV Pharmaceuticals July 15, 2008

  2. Slide 2: Forward-looking statements

    This presentation contains certain forward-looking statements that involve risks and uncertainties. Actual results and events may differ significantly from results and events discussed in forward-looking statements. Such forward-looking statements include, but are not Limited to, statements about th

  3. Slide 3: Additional Information About this Transaction

    Additional Information About this Transaction. In connection with the proposed merger, ViroPharma will file with the SEC a Registration Statement on Form S-4 that will include a ‘proxy statement of Lev that also constitutes a prospectus of ViroPharma. Lev will mail the proxy statement/prospectus to

  4. Slide 4: Vincent Milano, President and Chief Executive Officer

    « ViroPharma Incorporated Vincent Milano President and Chief Executive Officer

  5. Slide 5: LEV Represents an Ideal Strategic Fit

    y : 5 ViroPharma Incorporated 2S LEV Represents an Ideal Strategic Fit ® Company with late stage, clinically proven product with additional indication opportunities ® Targeting serious diseases with great medical need @ Markets addressable with small sales force ® Modest additional infrastructure re

  6. Slide 6: Cinryze is an Important Potential Therapy

    . ViroPharma Incorporated KY. = Cinryze™ is an Important Potential Therapy ® Cinryze is replacement therapy for patients with HAE (hereditary angioedema), a dangerous and rare disease @ Supported by 35+ years of replacement therapy experience in Europe ® Strong exclusivity proposition: US Orphan dru

  7. Slide 7: Deal Terms

    HED ViroPharma Incorporated rate 33 Deal Terms @ Total deal value $3.75/share, $617.5M aggregate value @ Upfront payment of $2.75/share, $442.9M payable in 82% cash and 18% VPHP stock ®@ Two contingent value right payments consistent with Cinryze success ® 0.50/share ($87.4M cash) on both approval a

  8. Slide 8: Colin Broom, M.D., Chief Scientific Officer

    « ViroPharma Incorporated Colin Broom, M.D. Vice President, Chief Scientific Officer

  9. Slide 9: Cinryze Clinical and Regulatory History

    o mi *: Cinryze™ Clinical and Regulatory History 2004: Orphan drug designation in HAE 2005: Fast track designation received in US 2007: Phase 3 data from prophylactic and acute trials presented 2007: Cinryze BLA submitted, including both sets of data 2008: Complete response letter received by Lev 20

  10. Slide 10: Cinryze Targeting: Hereditary Angioedema (HAE)

    «| Cinryze ™ on Targeting: Hereditary Angioedema (HAE) @ HAE is 4 life-threatening and debilitating genetic disorder ® Caused by a deficiency of C1 inhibitor (C1-INH) protein 2@ Autosomal dominantly inherited disease/50% chance of transmission to child @ Attacks last 2-3 days; on average, occur once

  11. Slide 11: Clinical Presentation of HAE

    y aa ee Clinical Presentation of HAE May lead to death from asphyxiation Often require intubation and tracheotomy Abe @ Associated with severe pain, intestinal obstruction, nausea, vomiting, and dehydration (® Lead to hospitalizations and unnecessary surgeries ee Result commonly from intercourse and

  12. Slide 12: Leading to a laryngeal attack

    Leading to a laryngeal attack =

  13. Slide 13: A Human Plasma Protein

    x A Human Plasma Protein... P ® Key regulator of three biochemical pathways: @ contact @ complement ® fibrinolysis PHARMA INCOMFDEATED .. that mediates inflammation @ C1 inhibitor deficiency can cause: @ disfiguring swelling @ debilitating pain ® asphyxiation & death 13

  14. Slide 14: Current Treatments Create Unmet Medical Need

    #3 Current Treatments Create Unmet Medical Need by Prophylaxis against HAE @ In US: Anabolic steroids (including Danazol) ® Underused ® Side effects of steroid use include liver toxicity, lipid abnormalities, carcinogenicity and virilization ® Limited usage among women and children @ In EU: anabolic

  15. Slide 15: Importance of prophylaxis

    a Hereditary Angioedema (HAE) es Importance of prophylaxis HAE is a dangerous disease; associated with up to 40% mortality if left untreated No way to tell if an attack will be deadly or how long an attack will take to develop C1 inhibitor used up more quickly during an acute attack, leading to an i

  16. Slide 16: Pivotal Phase Results from Cinryze

    a Pivotal Phase 3 Results from Cinryze™ Prophylactic Study Randomized, double-blind, placebo-controlled, multi-center study @ 22 subjects treated twice weekly @ History of at least 2 attacks per month to qualify ® Crossover design: 12 weeks of treatment in each arm for a total of 24 weeks @ Met prim

  17. Slide 17: Open label prophylactic trials

    @ More than 100 patients in open label prophylactic trials ®@ Provides revenue base at launch Carga vw

  18. Slide 18: Dan Soland, Chief Operating Officer

    Dan Soland Vice President, Chief Operating Officer Caras 18

  19. Slide 19: Status of Drugs in Development for HAE

    Lh & Status of Drugs in Development for HAE @ Multiple HAE drugs with Orphan Drug designation ®@ However, FDA have indicated that they are considering HAE prophylaxis and acute treatment separately for exclusivity ®@ Drugs with pivotal prophylactic data: 2 Only Lev’s Cinryze™ (C1 INH) @ Drugs with p

  20. Slide 20: U.S. HAE population (diagnosed)

    U.S. HAE population (diagnosed) 4,600* Acute market 3,100 Prophylaxis market 1,500 Treatments per year (6 per year) Treatments per year (1.5 per week) 18,600 117,000 Multi-hundred million dollar market opportunity in both acute and prophylaxis Pricing anticipated to be comparable to other ultra Cras

  21. Slide 21: Orphan drug comparables and annual costs

    Genzyme Gaucher's disease Genzyme Fabrazyme® Fabry disease Genzyme Myozyme® siauadiaa tt al Biomarin/Genzyme Aldurazyme® Hurler syndrome (MPS) Shire Elaprase™ Hunter syndrome (MPS II) Paroxysmal Nocturnal Hemoglbinuria (PNH) ) Vidimsens iicOMPORATED a Annual costs are approximate and may vary depend

  22. Slide 22: Understanding Today's HAE Landscape

    raat, ery ‘ Understanding Today’s HAE Landscape ee Source: LEV market research Bet Se ® 700+ allergists with 3,500+ HAE patients under care ® 175 docs manage 70% of patients @ ~1,500 patients are currently taking prophylactic anabolic steroid ®@ Only 34% of family members have been tested for HAE @

  23. Slide 23: Lack of Satisfaction Among Allergists

    Understanding Today’s HAE Landscape Lack of Satisfaction Among Allergists Source: LEV market research @ HAE treating allergists average of 6.5 HAE patients per practice @ 64% to 75% currently use prevention with steroids despite limitations @ Allergists unsatisfied with current prophylactic options

  24. Slide 24: Lack of Satisfaction Among HAE Patients

    Shy « Understanding Today’s HAE Landscape Lack of Satisfaction Among HAE Patients Source: LEV market research @ Patient unmet needs: prevention and symptom relief ® 66% take steroids, though very concerned about associated long-term health problems ®@ Strong preference to convert from Danazol to C1-

  25. Slide 25: Commercialization Plan in Place for Successful Launch

    * os Commercialization Plan in Place for Successful Launch ® Already executing on strong commercialization plan: ®@ Publication, patient association, KOL, internet, etc. plans underway ® Distribution strategy in place ®@ Patient Assistance Program ready to assure that every HAE patient would have ac

  26. Slide 26: Launch and Commercialization of Cinryze

    ¢s lead ak. ie ren ViroPharma Incorporated fs Bee i Launch and Commercialization of Cinryze™ 2 Fee ® Strong work in advance of approval by Lev team helps support successful launch ® ViroPharma’s commercial and regulatory experience and infrastructure, and capital, improve likelihood of success ® Add

  27. Slide 27: Vincent Milano, President and Chief Executive Officer

    Vincent Milano President and Chief Executive Officer Cram é

  28. Slide 28: LEV Acquisition Represents an Ideal Strategic Fit

    4 ViroPharma Incorporated 8 LEV Acquisition Represents an Ideal Strategic Fit e Opportunity to acquire another near term opportunity ® Multiple additional potential indications possible ® Fits VPHM business development requirements perfectly @ Niche product opportunity ® Targets serious disease; sig

  29. Slide 29: Acquisition of LEV Pharmaceuticals

    Y ‘ VIROPHARMA ' es Qk mk ‘ViroPharma Incorporated Acquisition of LEV Pharmaceuticals July 15, 2008

Lev Pharmaceuticals — Merger or Acquisition (July 2008) on 6ix